The Influence of Neuromuscular Reversal on Neurological Physical Exam Time in Lumbar Neurosurgical Cases.
The Influence of Neuromuscular Reversal With Neostigmine or Sugammadex on Neurological Physical Exam Time in Lumbar Neurosurgical Cases.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey
- Ankara University Faculty of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Lumber surgery
- ASA I-II
- Elective surgery
Exclusion Criteria:
- Emergency cases
- Age lower than 18
- Age higher than 65
- Patient with existing neurological deficit
- Patient with existing renal insufficiency
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group S
Group S: Group sugammadex Patients in this group received sugammadex at the end of the surgery, as neuromuscular reversal agent.
Neurological physical exam time was recorded.
|
Neurological physical exam is performed in all patients at the OR table, immediately after the operation.
|
|
Group N
Group N: Group Neostigmine Patients in this group received neostigmine at the end of the surgeryas neuromuscular reversal agent. Neurological physical exam time was recorded. |
Neurological physical exam is performed in all patients at the OR table, immediately after the operation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurological physical examination time
Time Frame: postoperative first 30 minutes
|
Neurological physical examination time
|
postoperative first 30 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle strength at PACU transfer
Time Frame: postoperative first 60 minutes
|
Muscle strength at PACU transfer (evaluated with a 5 point scale) 0/5: no contraction in muscles 1/5: muscle flicker but no movement 2/5: movement possible bıt not against gravity (test the joint in its horizontal plane) 3/5: moment possible against gravity but not against resistance by the examiner 4/5: movement possible against resistance by the examiner 5/5: normal strength
|
postoperative first 60 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Basak Ceyda MECO, MD, Ankara University Faculty of Medicine
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 10-544
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurological Complication
-
NCT05843214RecruitingNeurological Complication
-
NCT05097066CompletedSurgery | Surgery--Complications | Outcome, Fatal | Neurological Disorder | Morality | Neurological Morbidity | Neurological Complication | Comorbidities and Coexisting Conditions | Neurological Diseases or Conditions | Neurological Procedural Complication
-
NCT06360666Enrolling by invitationMortality | Nephrotoxicity | Respiratory Complication | Neurological Complication | Surgical Complication | Metabolic Complication | Cardiovascular Complication
-
NCT03493256CompletedNeurological Complication of Procedure (Disorder)
-
NCT04956835RecruitingAnesthesia Morbidity | Neurological Morbidity | Surgical Complication
-
NCT02067806CompletedNeurological Complication, in Particular TNS or CES
-
NCT05363098Not yet recruitingMechanical Ventilation Complication | Respiratory Complication | Neurological Complication
-
NCT03485612CompletedAnaesthetic Complication Neurological | Central Nervous System Depression
-
NCT05822557CompletedStroke | Cancer | Gastrointestinal Dysfunction | Neurological Disorder | Oral Complication
-
NCT03293472UnknownAnesthesia; Adverse Effect, Spinal and Epidural | Anaesthetic Complication Neurological
Clinical Trials on Neurological physical exam
-
NCT03586635CompletedMS CHRONIC PROGRESSIVE
-
NCT01776086WithdrawnInpatients With Normal Neurological Function
-
NCT03842215RecruitingPhysical Activity
-
NCT02572869Completed
-
NCT07137299Not yet recruitingEndometrial Hyperplasia | Abnormal Uterine Bleeding Unrelated to Menstrual Cycle | Pelvic Organ Prolapse (POP) | Uterine Fibroids (UF)
-
NCT06879275Not yet recruitingPrognathism | Psychiatric Disorders | Orthognathic Surgical Procedures
-
NCT06714578Not yet recruiting